Amgen Inc. (AMGN) Earnings Call Transcripts
Amgen Inc.'s Latest Earnings Call - Q2 FY2026
In Q2 2026, Amgen Inc. (AMGN:US) reported total revenues of over $10 billion, reflecting a 10% year-over-year increase, driven by strong performance across 22 products that achieved double-digit sales growth. Non-GAAP earnings per share (EPS) guidance was raised to a range of $22.30 to $23.50, indicating confidence in sustained growth. The company highlighted six key growth drivers, including Repatha and EVENITY, which saw significant sales increases, positioning Amgen for durable growth into the next decade.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $10B (beat) |
| Non-GAAP EPS | $22.30 - $23.50 (beat) |
| Operating Margin | 48% (positive) |
| Free Cash Flow | $3.5B (positive) |
| Biosimilars Sales | $855M (positive) |
| Prolia and XGEVA Sales | $1.1B (negative) |
Guidance from management
Amgen raised its 2026 total revenue guidance to a range of $38.2 billion to $39.4 billion and non-GAAP EPS guidance to between $22.30 and $23.50, reflecting strong confidence in future performance.
What management said
Thank you, Julianne. Good afternoon, everyone, and welcome to our second quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay Bradner and Peter Griffith. Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materi...
Okay. Thank you for that strong report, Pete. And before we open up to questions, let me just remind you that this is Pete's [indiscernible] earnings call with us. So I'll take a few minutes at the end of our Q&A to thank him and recognize his contributions to our firm. But now Julianne, let's open the line up for questions.
What analysts pressed on
Analysts expressed concerns regarding the impact of biosimilar competition on Prolia and XGEVA sales, which saw a significant decline. There were also questions about the sustainability of growth in the face of increasing competition in the cardiovascular space, particularly with the recent approval of Merck's oral PCSK9 inhibitor.
Main topics on the call
- Strong Revenue Growth — Amgen reported total revenues exceeding $10 billion, a 10% increase year-over-year. Management stated, "22 products delivered double-digit sales growth and 17 products annualized at more than $1 billion based on second q...
- Key Growth Drivers — The company's six key growth drivers grew at an aggregate rate of 26% year-over-year, representing nearly 70% of second quarter product sales. Management emphasized, "This broad-based performance is exactly what our stra...
- Pipeline Progress — Amgen's late-stage pipeline is advancing well, with MariTide, Olpasiran, and Xaluritamig progressing through Phase III development. Management noted, "We remain focused on disciplined execution and generating high-qualit...
- Guidance Update — Amgen raised its 2026 revenue guidance to a range of $38.2 billion to $39.4 billion and non-GAAP EPS guidance to between $22.30 and $23.50. This reflects confidence in the company's performance and growth trajectory.
Read the full Amgen Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Amgen Inc.
Amgen Inc. (AMGN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 133 calls on record spanning January 9, 2020 to August 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 133 Amgen Inc. earnings call transcripts on record, spanning January 9, 2020 to August 4, 2026. Based on this history, Amgen Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- AMGN
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 133
- First call
- January 9, 2020
- Most recent
- August 4, 2026
- Reporting cadence
- quarterly